Compare Canopy Growth Corp (CGC) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs JPMorgan Chase & Co — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while JPMorgan Chase & Co trades at $344.69 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 2287.5× Canopy Growth Corp's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | JPM | |
|---|---|---|
Market Cap | $398.46M | $911.47B |
Sector | Health | Financials |
52-Week High | $1.92 | $342.89 |
52-Week Low | $0.86 | $282.84 |
Enterprise Value | $337.90M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with $181.85B revenue in 2025 and net income of $57.05B, though recent earnings were mixed with a Q4 2025 miss but Q1 and Q2 2026 beats. Analyst consensus is moderately bullish with a $369.67 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
JPMorgan presents a solid investment case with robust profitability (31.61% net margin, 17.03% ROE) and reasonable valuation (P/E 14.69). Risks include geopolitical tensions impacting banking operations and cybersecurity threats from advanced AI. The stock offers upside to analyst targets but faces headwinds from economic uncertainty and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
